Literature DB >> 35022822

Involvement of oxidative pathways and BDNF in the antidepressant effect of carvedilol in a depression model induced by chronic unpredictable stress.

Caren Nádia Soares de Sousa1, Ingridy da Silva Medeiros1, Germana Silva Vasconcelos1, Gabriel Angelo de Aquino1, Francisco Maurício Sales Cysne Filho1, Jamily Cunha de Almeida Cysne1, Danielle Silveira Macêdo1, Silvânia Maria Mendes Vasconcelos2.   

Abstract

RATIONALE: Depression is a severe psychiatric disorder with oxidative imbalance and neurotrophic deficits as underlying mechanisms.
OBJECTIVES: Based on the antioxidant effects of carvedilol (CARV), here, we aimed to evaluate CARV's effects against depression induced by the chronic unpredictable stress (CUS) model.
METHODS: Female Swiss mice were submitted to the CUS protocol for 21 days. Between days 15 and 22, the animals received CARV (5 or 10 mg/kg) or desvenlafaxine (DVS 10 mg/kg) orally. On the 22nd day, mice were subjected to behavioral tests to evaluate locomotion, depressive-like behavior (tail suspension test), motivation/self-care with the splash test (ST), social interaction, and working memory Y-maze test. The prefrontal cortex (PFC) and hippocampus were dissected to evaluate alterations of oxidative and brain-derived neurotrophic factor (BDNF).
RESULTS: The CUS model reduced locomotion and increased grooming latency, while it reduced the number of groomings in the ST. Both doses of CARV and DVS reverted these alterations. In addition, DVS and CARV reversed CUS model-induced working memory and social interaction deficits. The CUS model decreased hippocampal reduced glutathione (GSH), while DVS and CARV increased GSH in the PFC (CARV5) and hippocampus (CARV5 and 10). The CUS model increased nitrite and malondialdehyde (MDA) concentrations in both areas. All treatments reversed nitrite alterations, while CARV10 changed MDA levels in PFC and all treatments in the hippocampus. The CUS model reduced BDNF levels. CARV10 increased BDNF in the PFC, while both doses of CARV increased hippocampal levels of this neurotrophin.
CONCLUSIONS: CARV presents antidepressant-like effects comparable to those observed with DVS. In addition, it has an antioxidant effect and is capable of increasing BDNF brain concentrations. Further studies are needed to elucidate the mechanisms involved in the antidepressant effect of CARV.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Brain-derived neurotrophic factor; Carvedilol; Chronic unpredictable stress; Depression; Oxidative stress

Mesh:

Substances:

Year:  2022        PMID: 35022822     DOI: 10.1007/s00213-021-05994-6

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  18 in total

1.  Neuroprotective evidence of alpha-lipoic acid and desvenlafaxine on memory deficit in a neuroendocrine model of depression.

Authors:  Caren Nádia Soares de Sousa; Lucas Nascimento Meneses; Germana Silva Vasconcelos; Ingridy da Silva Medeiros; Márcia Calheiros Chaves Silva; Fayçal Mouaffak; Oussama Kebir; Cláudio Manuel Gonçalves da Silva Leite; Manoel Cláudio Azevedo Patrocinio; Danielle Macedo; Silvânia Maria Mendes Vasconcelos
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-05-07       Impact factor: 3.000

2.  Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction.

Authors:  H Ohkawa; N Ohishi; K Yagi
Journal:  Anal Biochem       Date:  1979-06       Impact factor: 3.365

3.  Carvedilol attenuates inflammatory biomarkers and oxidative stress in a rat model of ulcerative colitis.

Authors:  Amal J Fatani; Khaled A Al-Hosaini; Mohammed M Ahmed; Hatem M Abuohashish; Mihir Y Parmar; Salim S Al-Rejaie
Journal:  Drug Dev Res       Date:  2015-06       Impact factor: 4.360

4.  Effects of carvedilol on an ischemia/reperfusion model: Biochemical, histopathological and immunohistochemical evaluation.

Authors:  Asker Zeki Özsoy; Ayşe Feyda Nursal; Akgül Arıcı; İlknur Bütün; Murat Uysal; Hilal Irmak Sapmaz; Çiğdem Kunt İşgüder; Hatice Yılmaz Doğru; Ufuk Taş
Journal:  J Obstet Gynaecol Res       Date:  2016-05-12       Impact factor: 1.730

5.  Neuropsychopharmacological effect of sesamol in unpredictable chronic mild stress model of depression: behavioral and biochemical evidences.

Authors:  Baldeep Kumar; Anurag Kuhad; Kanwaljit Chopra
Journal:  Psychopharmacology (Berl)       Date:  2010-11-20       Impact factor: 4.530

6.  Etazolate abrogates the lipopolysaccharide (LPS)-induced downregulation of the cAMP/pCREB/BDNF signaling, neuroinflammatory response and depressive-like behavior in mice.

Authors:  J Guo; P Lin; X Zhao; J Zhang; X Wei; Q Wang; C Wang
Journal:  Neuroscience       Date:  2014-01-13       Impact factor: 3.590

7.  Effect of Carvedilol on Secondary Damage in Experimental Spinal Cord Injury in Rats.

Authors:  Yasar Karatas; Sahika Liva Cengiz; Hasan Esen; Aysun Toker; Cigdem Savas
Journal:  Turk Neurosurg       Date:  2015       Impact factor: 1.003

Review 8.  The molecular neurobiology of depression.

Authors:  Vaishnav Krishnan; Eric J Nestler
Journal:  Nature       Date:  2008-10-16       Impact factor: 49.962

9.  What are 'good' depression symptoms? Comparing the centrality of DSM and non-DSM symptoms of depression in a network analysis.

Authors:  Eiko I Fried; Sacha Epskamp; Randolph M Nesse; Francis Tuerlinckx; Denny Borsboom
Journal:  J Affect Disord       Date:  2015-10-01       Impact factor: 4.839

10.  Role of antioxidant property of carvedilol in mild to moderate hypertensive patients: A prospective open-label study.

Authors:  Saleh Ayashi; Ahmad Reza Assareh; Mohammad Taha Jalali; Samaneh Olapour; Hamid Yaghooti
Journal:  Indian J Pharmacol       Date:  2016 Jul-Aug       Impact factor: 1.200

View more
  1 in total

Review 1.  Neurobiological Links between Stress, Brain Injury, and Disease.

Authors:  Hanmu Guo; Lexin Zheng; Heng Xu; Qiuyu Pang; Zhiyang Ren; Yuan Gao; Tao Wang
Journal:  Oxid Med Cell Longev       Date:  2022-05-25       Impact factor: 7.310

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.